Shares of Dermira, Inc. (NASDAQ:DERM) have received an average rating of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $43.80.

Several equities research analysts have weighed in on DERM shares. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Tuesday, July 18th. Evercore ISI started coverage on Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Zacks Investment Research downgraded Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald started coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock.

Dermira (NASDAQ DERM) traded up 2.57% during trading on Friday, reaching $23.12. The company had a trading volume of 132,981 shares. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75. The stock has a 50 day moving average price of $28.28 and a 200 day moving average price of $30.71. The firm’s market capitalization is $961.58 million.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.04. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1 million. Analysts predict that Dermira will post ($4.17) earnings per share for the current year.

In other Dermira news, SVP Christopher M. Griffith sold 1,312 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $27.07, for a total transaction of $35,515.84. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 16,812 shares of company stock worth $482,231 over the last ninety days. 13.30% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of DERM. BNP Paribas Arbitrage SA boosted its stake in Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC boosted its stake in Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. acquired a new stake in Dermira during the first quarter worth approximately $215,000. Legal & General Group Plc boosted its stake in Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 963 shares during the period. Finally, Tocqueville Asset Management L.P. acquired a new stake in Dermira during the first quarter worth approximately $256,000. Hedge funds and other institutional investors own 84.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Dermira, Inc. (DERM) Given Average Recommendation of “Hold” by Analysts” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/dermira-inc-derm-given-average-recommendation-of-hold-by-analysts/1473435.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.